Drug – bio-affecting and body treating compositions – Solid synthetic organic polymer as designated organic active... – Monomer contains oxygen
Reexamination Certificate
2006-02-27
2010-12-07
Vu, Jake M. (Department: 1618)
Drug, bio-affecting and body treating compositions
Solid synthetic organic polymer as designated organic active...
Monomer contains oxygen
C435S375000
Reexamination Certificate
active
07846426
ABSTRACT:
The present invention relates to compositions and methods for treating and preventing heart disease. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188—P188) and methods of using the same for treating and preventing heart disease (e.g., in subjects with muscular dystrophy) and for treating cells and tissue damage caused by ischemia and cell death (e.g., for treating dystrophin-deficient cells (e.g., myocytes)).
REFERENCES:
patent: 6342247 (2002-01-01), Ku et al.
patent: 6747064 (2004-06-01), Emanuele
patent: 6761824 (2004-07-01), Reeve
patent: 6977045 (2005-12-01), Reeve
patent: 02/065834 (2002-08-01), None
patent: 92/22202 (2002-12-01), None
Schaer et al (Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Circulation. Aug. 1, 1996;94(3):298-307).
Gibbs et al (Purified poloxamer 188 for sickle cell vaso-occlusive crisis. Ann Pharmacother. Feb. 2004;38(2):320-4. Epub Dec. 30, 2003).
Yasuda et al (Membrane Sealant Poloxamer 188 Corrects the Primary Defect Caused by Dystrophin Deficiency in Single Cardiac Myocytes from Mdx Mice. Circulation, vol. 110, No. 17, Suppl. S, Oct. 2004).
Finstere et al (The heart in human dystrophinopathies. Cardiology. 2003;99(1):1-19).
Adams-Graves et al., “RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study.” 1997 Blood 90 pp. 2041-2046.
Chareonthaitawee et al., “The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. For the CORE investigators (Collaborative Organisation for RheothRx Evaluation)” 2000 Heart 84:142-148.
Emanuele et al., “FLOCOR: a new anti-adhesive, rheologic agent.” 1998 Expert Opin Investig Drugs. 7:1193-1200.
Finsterer and Stollberger, “The heart in human dystrophinopathies.” 2003 Cardiology 99 pp. 1-19.
Gibbs and Hagemann, “Purified poloxamer 188 for sickle cell vaso-occlusive crisis” 2004 Ann. Pharmacother. 38:320-324.
Goyenvalle et al., “Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.” 2004 Science 306 pp. 1796-1799.
Gregorevic et al., “Systemic delivery of genes to striated muscles using adeno-associated viral vectors” 2004 Nat Med 10, pp. 828-834.
Grover et al., “Effect of a nonionic surface-active agent on blood viscosity and platelet adhesiveness” 1969 Circ. 39 and 40:I249 (Suppl. I ).
Hunt et al., “ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America.” 2001 Circulation 104:2996-3007.
Kabanov et al., “Pluronic block copolymers for overcoming drug resistance in cancer” 2002 Adv Drug Deliv Rev, 54, 758-779.
Kaprielian and Severs, “Dystrophin and the cardiomyocyte membrane cytoskeleton in the healthy and failing heart.” 2000 Heart Failure Reviews 5:221-238.
Kawada et al., “A novel paradigm for therapeutic basis of advanced heart failure—assessment by gene therapy” 2005 Pharmacol. Therap. 107:31-43.
Lee et al., “Pharmaceutical therapies for sealing of permeabilized cell membranes in electrical injuries.” 1999 Ann NY Acad Sci 888, 266-73.
Lee et al., “Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo.” 1992 Proc. Natl. Acad. Sci. USA 89:4524-4528.
Maskarinec et al., “Direct observation of poloxamer 188 insertion into lipid monolayers” 2002 Biophys. J. 82:1453-1459.
Michele et al., “Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by beta-blockade” 2002 Circ Res 91 pp. 255-262.
MODI, “Flocor CytRx Corp” 1999 IDrugs, Current Drugs Ltd, GB vol. 2 No. 4 366-374.
Muntoni, “Cardiomyopathy in muscular dystrophies” 2003 Curr. Opin. Neurol. vol. 16 pp. 577-583.
O'Keefe et al., “Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction” 1996 Am. J. Cardiol. 78:747-750.
Pasternak et al., “Mechanical function of dystrophin in muscle cells” 1995 J Cell Biol 128 pp. 355-361.
Raev,“Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients” 1994 Diabetes Care 17:633-639.
Schaer et al., “Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction: Results of a randomized, double-blind, placebo-controlled trial” 1996 Circ. (American Heart Association) 94:298-307.
Schmolka, “A Review of Block Polymer Surfactants” 1977 J. Am. Oil Chem. Soc. 54 pp. 110-116.
Shibata et al., “Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design”2002 Int J. Cardiol 86:77-85.
Squire et al., “Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system” 2002 Hum Mol Genet 11, 3333-44.
Straub and Campbell, “Muscular dystrophies and the dystrophin-glycoprotein complex” 1997 Curr Opin Neurol 10, 168-75.
Torrente et al., “Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscle” 2004 J Clin Invest 114,pp. 182-195.
Toth K. et al., “The effect of RheothRx injection on the hemorheological parameters in patients with acute myocardial infarction” 1997 Clinical Hemorheology and Microcirculation, Ios Press, Amsterdam vol. 17 No. 2 117-125.
Wu G. et al., “Lipid corralling and poloxamer squeeze-out in membranes” 2004 Phys Rev Lett 93 028101.
Yasuda Soichiro et al., “Dystrophic heart failure blocked by membrane sealant poloxamer” 2005 Nature vol. 436 No. 7053 1025-1029.
Yasuda So-Ichiro et al., “Membrane sealant poloxamer 188 corrects the primary defect caused by dystrophin deficiency in single cardiac myocytes from Mdx mice” 2004 Circulation vol. 110 No. 17, p. 135.
Zile and Brutsaert “New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment” 2002 Circulation 105:1503-8.
Examiner's Report, Australian Patent Application No. 2006216420 dated Feb. 27, 2009.
EP Supplementary Search Report, EP Patent Application No. 06 736 222.8 dated Sep. 29, 2008.
Baczko, et al., Pharmacological activation of plasma-membrane KATP channels reduces reoxygenation-induced Ca2 + overload in cardiac myocytes via modulation of the diastolic membrane potential, British Journal of Pharmacology, vol. 141, No. 6, pp. 1059-1067, Mar. 1, 2004.
Canadian Patent Application No. 2,599,219 Office Action dated Jul. 16, 2009.
Balghith, Mohammed, “Assessment of diastolic dysfunction after acute myocardial infarction using Doppler echocardiography,” Can J Cariol vol. 18 No. 1, Jan. 2002, pp. 69-77.
EP Patent Application No. 06 736 222.8 Search Dated Jan. 27, 2010.
Metzger Joseph M.
Michele Daniel E.
Townsend Dewayne
Yasuda Soichiro
Casimir Jones SC
The Regents of the University of Michigan
Vu Jake M.
LandOfFree
Compositions and methods for treating and preventing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating and preventing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating and preventing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4177086